Biocon Shares Jump 2.02% After U.S. FDA Clears Denosumab Biosimilars

Mumbai, September 18, 2025: Biocon Limited share price is up today, driven by strong investor demand. As of 12:15 PM, the shares are up by 2.02%, or 7.15 points, and are trading at ₹361.50. Until now, the shares have traded within a range of ₹364.75 and ₹358. The traded volume stands at 58.55 lakh shares, with the company market cap at ₹47,375 crore. The shares have their 52-week high at ₹405.90 and 52-week low at ₹290.80.

Biocon Limited is an Indian biopharmaceutical company that develops and manufactures medicines for chronic diseases such as diabetes, oncology, and autoimmune conditions. The company was founded on 29th November 1978, and its headquarters are in Bengaluru, Karnataka, India. Its NSE ticker symbol is BIOCON and BSE code is 532523.

Key Trigger: U.S. FDA Clearing Denosumab Biosimilars

The rise in the share price comes after the company announced that its subsidiary Biocon Biologics has received U.S. FDA approval for two denosumab biosimilars, Bosaya™ and Aukelso™. Apart from this, the company has also received provisional interchangeability status by the FDA. These approvals are likely to strengthen Biocon’s commercial positioning in the U.S. market.

Bosaya™ has been approved by the FDA for osteoporosis treatment in high-risk patients, while Aukelso™ has been approved for preventing skeletal-related events in cancer patients with bone metastases and other related conditions.

According to IQVIA data, denosumab products generated nearly $5 billion in U.S. sales in 2024, with Prolia contributing $3.3 billion and Xgeva $1.6 billion.

Significant Milestone For Biocon

Shreehas Tambe, CEO & Managing Director of Biocon Biologics, said: “The FDA’s approval of Bosaya™ and Aukelso™ is a significant milestone in our mission to expand access to critical biologic therapies. With Bosaya™, we are proud to offer a more affordable treatment option for patients with osteoporosis, and with Aukelso™, we are further expanding our oncology care portfolio.”

REF:https://www.bseindia.com/xml-data/corpfiling/AttachLive/c308330d-bc56-4a53-ac83-a96b5945ffe5.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations